STAINES-UPON-THAMES, United Kingdom, June 28, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has completed enrollment of the company's ongoing Phase 4
Growth Capitalist (https://growthcapitalist.com/2018/06/mallinckrodt-rheumatoid-arthritis-phase-4-clinical-study-for-h-p-acthar-gel-repository-corticotropin-injection-achieves-its-enrollment-target/)
STAINES-UPON-THAMES, United Kingdom, June 28, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has completed enrollment of the company's ongoing Phase 4